---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-012044"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:16:44.248275+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients

## Summary
- Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
- Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).
- Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.
- Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed.

## SEC filing metadata
- accession: 0001062993-25-012044
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/0001062993-25-012044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-012044
- JSON: https://secwatch.observer/filing/0001062993-25-012044.json
- Plain text: https://secwatch.observer/filing/0001062993-25-012044.txt

## Key facts
- Executive change
  Andrew Smith was appointed as Chief Operating Officer at Medicus Pharma Ltd..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/0001062993-25-012044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.